A $7.8 billion court stamp is a significant vote of confidence in a mechanism that, until recently, most sleep medicine investors treated as promising but distant. With the High Court of Justice of England and Wales sanctioning the scheme of arrangement on June 22, Eli Lilly’s acquisition of Centessa Pharmaceuticals is effectively done, with the transaction closing expected June 24 and Centessa’s Nasdaq-listed ADSs halting before that morning’s open. The structure tells you what Lilly actually believes: $38 per share in cash upfront, plus a contingent value right worth up to $9 per share tied to three FDA-approval milestones, putting the ceiling at roughly $1.5 billion in additional earnout on top of the $6.3 billion base.
The asset driving that price is Centessa’s orexin receptor 2 agonist program, anchored by ORX750. Phase 1 and Phase 2a data showed clinically meaningful, statistically significant improvements in mean sleep latency in sleep-deprived healthy volunteers, with the 2.5 mg dose already signaling the kind of effect size that late-stage development needs. A second candidate, ORX142, generated early Phase 1 data as well, giving Lilly two shots at the same pathway. The sleep disorder market is not empty: modafinil has been approved for narcolepsy-associated excessive sleepiness since December 1998, and pitolisant and others followed. But those options work through different mechanisms and leave a real clinical gap for patients who don’t respond adequately or tolerate existing agents, which is precisely the commercial opening Lilly is pricing into the CVR structure.
The deal logic here is less about plugging a revenue hole in Lilly’s near-term portfolio and more about owning a foundational biology position. Orexin signaling touches wakefulness, attention, cognition, and fatigue across neurological, neurodegenerative, and neuropsychiatric conditions. Lilly is not buying a narcolepsy drug; it is buying optionality across a pathway that could extend into Alzheimer’s-related cognitive symptoms, Parkinson’s fatigue, and beyond, all areas where Lilly already carries weight. That strategic breadth is what justifies paying a premium now and writing three milestone checks later. The scheme-of-arrangement structure, chosen because Centessa is a UK plc, required High Court sanction rather than a standard shareholder vote, adding a procedural step that is now cleared.
The single number to watch from here is the first CVR milestone trigger. The earnout terms are tied to specific FDA approvals for ORX750 or ORX142 in narcolepsy or related sleep disorders, and the timing of that first approval will tell the market whether Lilly bought a near-term commercial asset or a long-cycle pipeline bet.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
